

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

#21

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet 41	of 20		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
MKE		4,554,101		Hopp	11/19/85	
MKE		4,784,942		Harley	11/15/88	
MKE		4,865,970		Brot, et al.	09/12/89	
MKE		5,312,752		Woltz, et al.	05/17/94	
MKE		5,354,691		Van Eden, et al.	10/11/94	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
MKE			0 113 431A	EP		07/18/84		
MKE			0313 156	EP		04/26/89		
			WO 88/09932	PCT		08/03/88		
MKE			WO 91/17171	PCT		11/14/91		
			WO 91/11718	PCT		08/08/91		
MKE			WO 94/02445	PCT		02/03/94		
MKE			WO 94/02509	PCT		02/03/94		
MKE			WO 94/21669	PCT		09/29/94		
MKE			WO 96/37225	PCT		11/28/96		

Examine Signature	<i>MKE</i>	Date Considered	3/2/99
-------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) O I P E JAN 21 1999 PATENT & TRADEMARK OFFICE		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
Sheet 2 of 20	Attorney Docket Number	OMRF 161	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
mkz		Alexander, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," <u>Arth. And Rheum.</u> 35:176-189 (1992)	
mkz		Banerjee, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," <u>Virology</u> 137:432-438 (1984)	
		Baraket, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <u>Clin. Exp. Immunol.</u> 89:38-45 (1992)	
mkz		Baraket, et al., "Mapping of Epitopes on U1 snRNP Polypeptide A with Synthetic Peptides and Autoimmune Sera," <u>Clin. Exp. Immunol.</u> 86(1):71-78 (October, 1991)	
mkz		Baraket, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," <u>Clin. Exp. Immunol.</u> 81:256-262 (1990)	
		Ben Chetrit, et al., "Isolation and Characterization of a August 3, 1997 cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <u>J. Clin. Inv.</u> 83:1284-1292	
mkz		Blank, M., et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," <u>Clin. Exp. Immunol.</u> 79:443-447 (1990)	
mkz		Blank, M., et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," <u>J. Autoimmunity</u> 1:683-591 (1988)	
mkz		Blank, M., et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA. Idiotype in Naive Mice," <u>J. Rheumatol.</u> 17:311-317 (1990)	
mkz		Blank, M., et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype," <u>J. Autoimmunity</u> 5:495-509 (1992)	

Examiner's Signature	<u>mkz</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) JAN 21 1999 PATENT & TRADEMARK OFFICE		Complete if Known	
		Application Number	08/781,296
Filing Date	January 13, 1997		
First Named Inventor	John B. Harley		
Group Art Unit	1815		
Examiner Name	Mary K. Zemen		
Attorney Docket Number	OMRF 161		
Sheet 3	of 20		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKZ		Blank, M., et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id+) and for Mouse Tuberculosis Antibody TB/68 (16/6 id+) <u>Clin. Immunol. Immunopathol.</u> 60:471-483 (1991)	
MKZ		Bray, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis", <u>Arch. Neurology</u> , 40:406-408 (1983)	
MKZ		Bray, et al., Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities between EBNA and Myelin Basic Protein, " <u>Arch. Neurol.</u> , (1992)	
MKZ		Buyon, "Neonatal Lupus Syndrome," <u>Curr. Opin. In Rheum.</u> 6:523-529 (1994)	
MKZ		Chambers, J. et al., "Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen," <u>J. Biol. Chem.</u> 263:18043-18051 (1988)	
		Chambers, J., et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <u>Proc. Natl. Acad. Sci. USA</u> 82:2115-2119 (1985)	
		Chan, E.K.L., et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <u>Nucl. Acids Res.</u> 17:2233-2244 (1989)	
MKZ		Cohen, "The Self, the World and Autoimmunity," <u>Scientific American</u> 258:52-60 (1988)	
MKZ		Craft, et al., "Murine and Drosophila B Proteins of SM snRNPS," <u>Mol. Biol. Rep.</u> , 15:159 (1991)	
MKZ		Crone, e al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," <u>Journal of Virology</u> 63(10):4172-4180 (1989)	

Examiner's Signature	<u>MKZ</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	4	of	20

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
MKZ		Cunningham, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," <u>Journal of Immunology</u> 141(8):2760-2766 (1988)	
MKZ		Dalldorf, et al., "The Lymphomas of Brazilian Children", <u>J. Am. Med. Assn.</u> , 208:1365-8 (1969)	
MKZ		Deacon, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome", <u>Am J. Med.</u> , 92:453-454 (1992)	
MKZ		Deacon, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome", <u>J. Pathol.</u> , 163:351-360 (1991)	
MKZ		DePolo, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," <u>J. of Virology</u> 61:454-464	
MKZ		Deutscher, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," <u>Proc. Natl. Acad. Sci. USA</u> 85:9479-83 (1988)	
		Dickey, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lups Association, Inc., Sept. 1, 1989.	
MKZ		Dyrberg and Oldstone, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," <u>Current Topics in Microbiology and Immunology</u> , 130:25-37 (1986)	
		Elkon, K., et al., "Epitope Mapping of Recombinant HLA Smb and B* Peptides Obtained by the Polymerase Chain Reaction," <u>J. of Immun.</u> 145:636-643 (1990)	
MKZ		Esquivel, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," <u>J. Exp. Med.</u> , 145:1250-1263 (1977)	

Examiner's Signature	<u>MKZ</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	5	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
mkz		Evans, "E.B. Virus Antibody in Systemic Lupus Erythematosus" <u>Lancet</u> , 1:1023-4 (1971)	
mkz		Evans, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:167-168 (1970)	
mkz		Evans & Rothfield, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:1127-1128 (1973)	
mkz		Evans & Niederman, Epstein-Barr virus. In <u>Viral Infections in Humans</u> , 3rd ed. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989)	
mkz		Evans, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 325-324 (1973)	
mkz		Ferris and Donaldson, <u>Veterinary Microbiology</u> 18(3-4):243-258 (1988)	
mkz		Finerty, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector", <u>J. Gen. Virol.</u> , 73:449-453 (1992)	
mkz		Finerty, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <u>Vaccine</u> , 12:1180-1184 (1994)	
mkz		Fox, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis", <u>J. Rheumatol.</u> , 19:18-24 (1992)	
mkz		Fox, "Sjogren's Syndrome", <u>Current Opin. Rheum.</u> , 7:409-416 (1995)	

Examiner's Signature		Date Considered	3/2/98
----------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	6	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
MRZ		Fox, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome", <u>J. Immunol.</u> , 137:3162-3168 (1986)	
MRZ		Fricke, H., et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," <u>Intern. Immunol.</u> 2:225-230 (1990)	
MRZ		Fritz, et al., "Small Nuclear U-Ribonucleoproteins in <i>Xenopus Laevis</i> Development," <u>J. Mol. Biol.</u> 178:273-285 (1984)	
MRZ		Gaither, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" <u>Peptides Biol. Fluids</u> 33:413-416 (1985)	
MRZ		Gaither, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity", <u>J. Clin. Invest.</u> , 79:841-846 (1987)	
MRZ		Gallione, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," <u>Virology</u> 39-529-535 (1981)	
MRZ		Gergely, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:325-326 (1973)	
MRZ		Geysen, et al., "Strategies for Epitope Analysis Using Peptide Synthesis," <u>J. of Immunol. Meth.</u> , 102:259-274 (1987)	
MRZ		Geysen, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <u>Proc. Natl. Acad. Sci. USA</u> 81:3998-4002 (1984)	
MRZ		Grabowski, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO", <u>Nucleic Acids Research</u> , 19(15):4297 (1987)	
MRZ		Gu, et al., <u>Dev. Biol. Stand.</u> , 84:171-177 (1995)	

Examiner's Signature	<i>MRZ</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	7	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKZ		Guldner, et al., <u>The Journal of Immunology</u> , 141(2):469-475 (July 15, 1988)	
MKZ		Gutierrez, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia", <u>Cancer Res.</u> , 56:969-972 (1996)	
MKZ		Haahr, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease", <u>Ann. N. Y. Acad. Sci.</u> , 724:148-156 (1996)	
MKZ		Hahn, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" <u>Springer Seminars in Immunopathology</u> , 7(1):25-34 (1984)	
MKZ		Hardgrave, et al., "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <u>Arthritis and Rheumatism</u> , 36(7):962-970	
MKZ		Harley & Gaither, "Autoantibodies" <u>Rheum. Dis. Clin. N. Amer.</u> , 14:43-56 (1992)	
MKZ		Harley, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome", <u>Arthritis Rheum.</u> , 29:196-206 (1986)	
MKZ		Harley & James, "Review Articles: Autoepitopes in Lupus", <u>J. Lab. Clin Med.</u> , 126(6):509-516 (1995)	
MKZ		Harley, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjorgren's Syndrome," <u>Science</u> 232:1145-1147 (1986)	
MKZ		Herbert, et al., <u>Dictionary of Immunology</u> 3 rd Ed. Blackwell Scientific Publications Oxford UK page 14 91985)	
MKZ		Heslop, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes", <u>Nature Med.</u> , 2:551-555 (1996)	

Examiner's Signature	<u>MKZ</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	8	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		Hinterberger, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs", <u>Biol. Chem.</u> , 258:2604-2613 (1983)	
MKB		Hollinger, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus", <u>Bact. Proc.</u> , 131:174 (1970)	
MKB		Horsfall, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," <u>J. of Autoimmun.</u> 4:165-176 (1991)	
MKB		Huang, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," <u>Scand. J. Immunol.</u> 41:220-228 (1995)	
MKB		Huang, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," <u>J. Investig. Med.</u> 43:151-158 (1995)	
MKB		Hurd, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid", <u>Arthritis Rheum.</u> 13:724-33 (1970)	
MKB		Inoue, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis", <u>J. Infect. Dis.</u> , 164:22-28 (1991)	
MKB		Ishii, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection", <u>Immunol. Cell Biol.</u> , 73:463-468 (1995)	
MKB		James, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <u>Scand. J. Immunol.</u> 39:557-566 (1994)	
MKB		James, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity", <u>J. Exp. Med.</u> , 181:453-461 (1995)	
MKB		James, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization", <u>Arthritis Rheum.</u> 38:S226 (1995)	

Examiner's Signature	<u>MKB</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	9	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		James & Harley, "Linear Epitope Mapping of an Sm B/B' Polypeptide", <u>J. Immunol.</u> , 148:2074-2079 (1992)	
MKB		James & Harley, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns", <u>J. Immunol.</u> , 4018-4026 (1996)	
MKB		James, et al., "Lupus Humoral Autoimmunity After Short Peptide Immunization", <u>Arthritis Rheum.</u> , 39:S216 (1996)	
MKB		James & Harley, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C," <u>Clin. And Exp. Rheum.</u> , 13:299-305 (1995)	
MKB		James, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL lpr/lpr Antibodies", <u>Clin. Exp. Immunol.</u> , 98:419-426 (1994)	
MKB		James and Harley, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C," <u>Clinical Res.</u> , 41(2):PA393 (1993)	
MKB		Kalush, et al., "Neonatal Lupus Erythematosus with Cadian Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," <u>J. of Clin. Immunol.</u> , 14:314-321 (1994)	
MKB		Karameris, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome", <u>Clin. Exp. Rheum.</u> , 10:327-332 (1992)	
MKB		Kaufman, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Anklosing spondylitis Pathogenesis", <u>UCLA School of Medicine</u> (abstract)	
MKB		Kieff & Liebowitz, D.: Epstein-Barr virus and its replication. In <u>Virology</u> , 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990)	

Examiner's Signature	<u>MKB</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	10	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
MKZ		* Kitagawa, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <u>Immunol. Lett.</u> , 17:249-252 (1988)	
MKZ		Klippel, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus", <u>Lancet</u> , 2:1057-1058 (1973)	
MKZ		Kurilla, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," <u>Cell</u> 34:837-845 (1983)	
MKZ		Kuzushima, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection", <u>Clin. Exp. Immunol.</u> , 103:192-298 (1996)	
MKZ		Larsen, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis", <u>Neurology</u> , 35:435-438 (1985)	
MKZ		Lazarovits, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation", <u>Clin. Invest. Med.</u> , 17:621-625 (1994)	
MKZ		Lerner & Steitz, "Antibodies to Small Nuclear PNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus", <u>Proc. Natl. Acad. Sci. USA</u> , 76:5495-5499 (1979)	
MKZ		Lee, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," <u>Am. J. of Med.</u> 83:793-796 (1987)	
MKZ		Lee, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus", <u>J. Investigative Dermatology</u> , 107(1):225-228 (1996)	
MKZ		Leff, "Maverick Herpes Receptor Sparks Search for KS Drug", <u>Bio World Today</u> , 8(17):1 (1997)	
MKZ		Lehman, et al., "Spreading of T-Cell Autoimmunity to Cryptic Determinants of an Autoantigen," <u>Nature</u> 356:155-157 (1992)	

Examiner's Signature	<i>MKZ</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	11	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
MKB		Lerner, et al., "Are snRNPs Involved in Splicing?" <u>Nature</u> 283:220-224 (1980)	
MKZ		Levitskaya, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1", <u>Nature</u> , 375:685-688 (1995)	
MKB		Maddison, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," <u>Arthritis Rheum.</u> 20:819-824 (1977)	
MKB		Maitland, "Frequency of EBV-DNA Detection in Sjogren's Syndrome", <u>Am. J. Med.</u> , 96:97 (1994)	
MKB		Manfredi, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <u>J. Lab. Clin. Med.</u> 120:13-21 (1992)	
MKB		Mariette, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome", <u>Am. J. Med.</u> , 90:286-294 (1991)	
MKB		Matter, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <u>Arthritis Rheum.</u> 25:1278-1283 (1982)	
MKE		Mattioli, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the SM and RNA protein (MO) Systems in SLE Sera," <u>J. Immunol.</u> 110:1318-1324 (1973)	
		McAllister, G., et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential 3m Epitope," <u>EMBO Jour.</u> 8:1177-1181 (1989)	
MKB		Mendlovic, S., et al., "The Genetic Regulation of the Induction of Experimental SLE," <u>Immunology</u> 69:228-236 (1990)	
MKB		Mendlovic, S., et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," <u>Eur. J. Immunol.</u> 19:729-732 (1989)	

Examiner's Signature	<u>MKB</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Complete if Known		
		Application Number	08/781,296	
Filing Date	January 13, 1997			
First Named Inventor	John B. Harley			
Group Art Unit	1815			
Examiner Name	Mary K. Zemen			
Attorney Docket Number	OMRF 161			
Sheet	12	20		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		Mendlovic, S., et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotypic," <u>Proc. Natl. Acad. Sci. USA</u> 85:2260-2264 (1988)	
MKB		Miller, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maintenance of Autoimmunity," <u>Proc. Natl. Acad. Sci. USA</u> 87:9933-9937 (1990)	
		Miller, Epstein-Barr virus. pp. 1921-1958,	
MKB		Miyashita, et al., "A Novel Form of Epstein-Barr Virus Latency in Normal B Cells In Vivo", <u>Cell</u> , 80:593-601 (1995)	
MKB		* Morgan, "Epstein-Barr Virus Vaccines," <u>Vaccine</u> , 10:563-571 (1992).	
MKB		* Morgan, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," <u>J. Med. Virol.</u> , 29:74-78 (1989)	
MKB		Morland, et al., "Anti-idiotypic and Immunosuppressant Treatment of Murine Lupus", <u>Clin. Exp. Immunol.</u> , 83(1):126-132 (1991)	
MKB		Morshed, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients", <u>Gastroenterol. Jpn.</u> , 27:751-758 (1992)	
MKB		Mosier, et al., <u>Nature</u> 335:256-259 (1988)	
MKB		Munves, et al., "Antibodies to Sm and RNP," <u>Arthritis Rheum.</u> , 26: 848-853 (1983)	
MKB		Newell & Stevens, "E.B. Virus Antibody in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:652 (1971)	

Examiner's Signature		Date Considered	3/2/99
----------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	20		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
mkz		Newkirk, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome", <u>Br. J. Rheum.</u> , 33:317-322 (1994)	
mkz		Ohosone, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen: Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," <u>Proc. Natl. Acad. Sci. USA</u> 86:4249-4253 (1989)	
mkz		Palfi, et al., "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," <u>Nucleic Acids Res.</u> 17:1445-1458 (1989)	
mkz		Petersen, et al., "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus", <u>Arthritis Rheum.</u> , 33: 993-1000 (1990)	
mkz		Petterson, et al., "The Structure of Mammalian Small Nuclear Ribonucleoproteins", <u>J. Biol. Chem.</u> , 259:5907-5914 (1984)	
mkz		Pflugfelder, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome", <u>Am. J. Pathol.</u> , 143:49-64 (1993)	
mkz		Pflugfelder, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients", <u>Ophthalmology</u> , 97:976-984 (1990)	
mkz		Phillips & Christian, "Myxovirus Antibody Increases in Human Connective Tissue Disease", <u>Science</u> , 168:982-4 (1970)	
mkz		Phillips, et al., "Viruses and Systemic Lupus Erythematosus", <u>Lancet</u> , 1:1449 (1973)	
mkz		Qualtiere & Pearson, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-1 Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Produced Culture Activated with Tumor	
mkz		Query, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," <u>Cell</u> 57:89-101 (1989)	

Examiner's Signature	<u>mkz</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. DMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) JAN 21 1999 PATENT & TRADEMARK OFFICE		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	20		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MRB		Ravirajan & Staines, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" <u>Immunology</u> , 74:342-347 (1991)	
MRB		Reichlin, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," <u>Clin. Exp. Immunol.</u> 83:286-290 (1991)	
MRB		Reichlin, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," <u>Arth. And Rheum.</u> 37:1698-1703 (1994)	
MRB		Renz, M., et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in <i>Escherichia coli</i> and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," <u>Clin. Chem.</u> 35:1861-1863 (1989)	
MRB		* Reuter, et al., "Immunization of Mice with Purified U1 Small Nuclear Ribonucleoprotein (RNP) Induces a Pattern of Antibody Specificities Characteristic of the Anti-Sm and Anti-RNP Autoimmune Response of Patients with Lupus Erythematosus, As Measured by Monoclonal Antibodies," <u>PNAS</u> 83:8689-8693 (1986)	
MRB		Rhodes, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Cyclic-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen", <u>J. Exp. Med.</u> , 165:1026-1040 (1987)	
MRB		Rokeach, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," <u>Proc. Natl. Acad. Sci. USA</u> 85:4832-36 (1988)	
MRB		Rokeach, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis", <u>J. Biol. Chem.</u> , 264:5024-30 (1989)	
MRB		Rose, et al., "T-Cell Regulation in Autoimmune Thyroiditis," <u>Immunol. Reviews</u> 55:229-314 (1981)	
MRB		Rose, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. ed. <u>Autoimmunology Genetic Immunologic Virologic, and Clinical Aspects</u> . New York: Academic Press, 63-87 (1977)	
MRB		Rose, et al., "Studies on Experimental Thyroiditis," <u>Ann. NY Acad. Sci.</u> 124:201-108 (1965)	

Examiner's Signature	<i>MRB</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	15	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		Sabbatini, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA 1", <u>Eur. J. Immunol.</u> , 23:1146-1152 (1993)	
MKB		Saito, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with Sjogren's Syndrome", <u>J. Exp. Med.</u> , 169:2191-2198 (1989)	
MKB		Sasaki, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin", <u>The Journal of Immunology</u> , 142(4):1159-1165 (1989)	
		Schaack, "Molecular Mimicry in HLA-B-27-Related Arthritis", <u>Annals of Internal Medicine</u> , 111(7):591-591 (October 1, 1989)	
MKB		Schmauss, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)", <u>Nuc. Acid Res.</u> , 17:1733-43 (1989)	
MKB		Scofield, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus", <u>Proc. Natl. Acad. Sci. USA</u> , 88:3343-3347 (1991)	
MKB		Scofield, R., "A Common Autoepitope Near the carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," <u>Journal of Clinical Immunology</u> 11(6):378-388 (1991)	
MKB		Scofield, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Homologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <u>Clinical Research</u> , 38(2):316A, (1990)	
MKB		Scofield, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus", <u>Arthritis & Rheumatism</u> , 39(10):1664-1688 (1996)	
MKB		Scofield, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity", <u>J. Immunology</u> , 4059-4066 (1996)	

Examiner's Signature	<i>MKB</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	16	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		Scofield, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome", <u>Clin. Exp. Rheum.</u> , 14:321-330 (1996)	
MKB		Scofield, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies", <u>Lancet</u> , 345:1542-1544 (1995)	
MKB		Sculley, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides", <u>J. Gen. Virol.</u> , 67:2253-2258 (1986)	
		Sharpe, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reacting with Human Anti-Sm Auto-", <u>FEBS Lett.</u> , 250:585-590 (1989)	
MKB		Shoenfeld, et al., "Modulation of Experimental SLE Induced in Naive Mice by a Pathogenic Anti-DNA Idiotype (16/6 id)," <u>Proceedings of the Second International Conference on Systemic Lupus Erythematosus Tokyo, Japan Professional Postgraduate Services 83</u> (1989)	
MKB		Shoenfeld, et al., "Pathogenic Idiotypes of Autoantibodies in Autoimmunity: Lessons from New Experimental Models of SLE," <u>FASEB J.</u> 4:2646-2651 (1990)	
MKB		Sillikens, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals," <u>Nucleic Acids Res.</u> 16:8307-21 (1988)	
MKB		Sillikens, P., et al., "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins," <u>EMBO Journal</u> 6:3841-3848 (1987)	
MKB		Singh, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?", <u>Digestive Dis. Sci.</u> 39:15-18 (1994)	
MKB		Spritz, et al., "The Human U1-70K s.n. RNP Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," <u>Nucleic Acid Res.</u> 15:10373-91 (1987)	
		Sturgess, A., et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," <u>J. Immun.</u> 3212-3218 (1988)	

Examiner's Signature	<i>MKB</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	17	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
mkz		Sumaya, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis", <u>Ann. Neurol.</u> , 17:371-377 (1985)	
mkz		Suzuki, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors", <u>J. Exp. Med.</u> , 182:477-486 (1995)	
mkz		Takeda, Y., et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," <u>Chem. Abstracts</u> 116(1): ab. No. 4803a (January 6, 1992)	
mkz		Tan, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus", <u>Arthritis Rheum.</u> , 25:1271-1277 (1982)	
mkz		Tan, et al., "Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," <u>J. Immunol.</u> 96:464-471 (1966)	
mkz		Tateishi, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome", <u>Arthritis Rheum.</u> , 36:827-835 (1993)	
mkz		Theissen, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," <u>EMBO J.</u> 5:3209-17 (1986)	
mkz		Tigbe, Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes, presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989)	
mkz		Tincani, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotype," <u>Clinical and Exp. Rheum.</u> 11:129-134 (1993)	
mkz		Toda, et al., Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation. In <u>Lacrimal Gland, Tear Film, and Dry Eye Syndrome</u> . D.A. Sullivan, ed. pp 647-650 (Plenum Press, New York 1994)	
mkz		Tsai, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus", <u>Int. Arch. Allergy Immunol.</u> , 106:235-240 (1995)	

Examiner's Signature	<i>mkz</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	18	20	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MXB		Tsuzuka, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S11," <u>Arthritis & Rheumatism</u> , 38(9):abstract 726 (1995)	
MXB		Tzartos, et al., "The Main Immunogenic region of the Acetylcholine Receptor. Structure and Role in Myasthenia Gravis," <u>Autoimmunity</u> 8:259-270 (1991)	
MXB		van Dam, et al., "Cloned Human snRNP Proteins B and B' Differ Only in Their Carboxy-Terminal Part", <u>EMBO J.</u> , 8(12):3853-3860 (1989)	
MXB		Van Venrooij, et al., "B Cell Epitopes on Nuclear Autoantigens," <u>Arthritis and Rheumatism</u> 37(5):608-616 (1994)	
MXB		Venables, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome", <u>Clin. Exp. Immunol.</u> , 75:359-364 (1989)	
MXB		Venables, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome", <u>J. Autoimmunity</u> , 2:439-448 (1989)	
MXB		Virji and Heckels, "Location of a Blocking Epitope on Outer-membrane Protein III of Neisseria Gonorrhoeae by Synthetic Peptide Analysis," <u>J. of Gen. Microbiol.</u> 135:1895-1899 (1989)	
MXB		Voller and Bidwell, "Enzyme-Linked Immunosorbent Assay," <u>Manual of Clinical Laboratory Immunology</u> (Chapter 17) (1986)	
MXB		Wait, K., et al., "Anti-Jo-1 antibodies are Directed at an Evolutionarily-conserved Conformational Site on Human Histidyl-tRNA Synthetase," <u>Mol. Cell Biol. Autoantibodies Autoimm.</u> 100:101 (1989)	
MXB		Wagstaff, et al., <u>Drugs</u> , 47:153-205 (1994)	
MXB		Waltuck and Buyon, "autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," <u>Ann. Intern. Med.</u> 120:544-551 (1994)	

Examiner's Signature	<u>MXB</u>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) JAN 21 1999 PATENT & TRADEMARK OFFICE		Application Number	08/781,296
		Filing Date	January 13, 1997
		First Named Inventor	John B. Harley
		Group Art Unit	1815
		Examiner Name	Mary K. Zemen
		Attorney Docket Number	OMRF 161
Sheet	20		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
MKB		Warner & Carp, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis", <u>Med. Hypotheses</u> , 25:93-97 (1988)	
MKB		Watson, et al., "Certain Properties Make Substances Antigenic," in Molecular Biology of the Gene, Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987)	
MKB		Whittingham, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome", <u>Med. Hypothesis</u> , 22:373-386 (1987)	
MKB		Williams, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," <u>J. Autoimmunity</u> 3:715-725 (1990)	
MKB		Wilson, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon-α2b", <u>Blood</u> , 87:4531-4537 (1996)	
MKB		Winfield, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," <u>Arthritis Rheum.</u> 21:289-294 (1978)	
MKB		Witebsky, et al., "Chronic Thyroiditis and Autoimmunization," <u>J. Am. Med. Assoc.</u> , 164:1439-1447 (1957)	
MKB		Xie & Snyder, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus", <u>Proc. Natl. Acad. Sci.</u> , 92:1639-1643 (1995)	
		Yamamoto, K., et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <u>J. Immun.</u> 140:311-317 (1988)	
MKB		Yokochi, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus", <u>J. Rheumatol.</u> , 16:1029-1032 (1989)	
MKB		Zeller, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiled snRNA-Binding Proteins During Oogenesis and Early Development in <i>Xenopus laevis</i> ," <u>Cell</u> 32:425-434 (1983)	

Examiner's Signature	MKB	Date Considered	3/2/99
----------------------	-----	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#17

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <p style="text-align: center; font-size: 1.2em; font-weight: bold;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>		<p style="text-align: center; font-weight: bold;">Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">Application Number</td> <td>08/781,296</td> </tr> <tr> <td>Filing Date</td> <td>January 13, 1997</td> </tr> <tr> <td>First Named Inventor</td> <td>John B. Harley</td> </tr> <tr> <td>Group Art Unit</td> <td>1815</td> </tr> <tr> <td>Examiner Name</td> <td>Mary K. Zeman</td> </tr> <tr> <td>Attorney Docket Number</td> <td>OMRF 161</td> </tr> </table>		Application Number	08/781,296	Filing Date	January 13, 1997	First Named Inventor	John B. Harley	Group Art Unit	1815	Examiner Name	Mary K. Zeman	Attorney Docket Number	OMRF 161
Application Number	08/781,296														
Filing Date	January 13, 1997														
First Named Inventor	John B. Harley														
Group Art Unit	1815														
Examiner Name	Mary K. Zeman														
Attorney Docket Number	OMRF 161														

OIPE JC58
 DEC 07 1998
 PATENT & TRADEMARK OFFICE

[illegible]

Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T2
MKZ		Rhodes, et al. "Human Immune responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen," <i>J. Immunol.</i> 134:211-216 (1985).	

RECEIVED
 GROUP 130
 DEC - 9 AM 8:03

GROUP 130
SEC-9 AN 8:03
134-11-216

Examiner's Signature	<i>myz</i>	Date Considered	3/2/99
----------------------	------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+